Double-blind crossover trial of gabapentin in SPG4-linked hereditary spastic paraplegia.
Patients with hereditary spastic paraplegia (HSP) are often treated with antispastic drugs to relieve symptoms but documentation is lacking. In this study, gabapentin was tested in a double-blind crossover trial on a group of patients with HSP and linkage to the SPG4 locus. There was no difference between periods with gabapentin and placebo treatment in clinical assessment, self-reported parameters or paired transcranial magnetic stimulation evaluation of motor cortical excitability.
Scheuer
K H
KH
Department of Neurology, Hillerød Hospital, Denmark. kristin@scheuerhome.dk
Svenstrup
K
K
Jennum
P
P
Rogvi-Hansen
B á
Bá
Werdelin
L
L
Fenger
K
K
Nielsen
J E
JE
D000251:Adenosine Triphosphatases / Q000235:genetics*; D000328:Adult; D000368:Aged; D000588:Amines / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use*; D018592:Cross-Over Studies; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008297:Male; D008875:Middle Aged; D015419:Spastic Paraplegia, Hereditary / Q000188:drug therapy* / Q000235:genetics*; D000074181:Spastin; D018709:Statistics, Nonparametric; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use*
D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D000251:Adenosine Triphosphatases; D000074181:Spastin; C400283:SPAST protein, human